NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced record results for the second quarter and first half ended June 30, 2021. The Company also posted its second quar…
Author: Business Wire
Dry Macular Degeneration Drugs Development Landscape Report 2021: Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry (Atrophic) Macular Degeneration (Ophthalmology) – Drugs in Development, 2021” report has been added to ResearchAndMarkets.com’s offering. Dry (Atrophic) Macular Degeneration (Ophthalmology) – Drugs in Development, 2021…
Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital
SAN DIEGO–(BUSINESS WIRE)–Sydnexis, Inc., a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led b…
National Vision Wins Two Awards Celebrating Gender Diversity
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, announced today that it has received two recent awards for gender diversity. N…
Lineage to Present at the H.C. Wainwright Ophthalmology Conference on August 17, 2021
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #LineageCellTherapeutics–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced t…
Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today a…
Daniela Drago Joins Aurion Biotech as Chief Regulatory Officer
SEATTLE & BOSTON & TOKYO–(BUSINESS WIRE)–Aurion Biotech appoints Daniela Drago, PhD, RAC, FRAPS, FTOPRA, as Chief Regulatory Officer
Visus Therapeutics Secures $20 Million in Additional Financing Led by New Investor LSP, with Participation from Sage Partners
SEATTLE–(BUSINESS WIRE)– #VC–Visus Therapeutics secures $20 million in additional financing led by new investor LSP in Amsterdam, with participation from Sage Partners.
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today reported financial res…
Omeros Corporation Reports Second Quarter 2021 Financial Results
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications ta…
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today r…
AOPO Joins with National Partners to Boost Number of Minority Organ Donors
MCLEAN, Va.–(BUSINESS WIRE)– #AOPO–Association of Organ Procurement Organizations addresses need for more organ donors within minority communities with new action plan and partnership.
Global Uveitis Epidemiology Forecast Research Report 2021-2029 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Uveitis – Epidemiology Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. The report includes a 10-year epidemiological forecast for the diagnosed incident and diagnosed prevalent cases of uveiti…
Le groupe Polpharma Biologics annonce que sa coentreprise Bioeq a soumis une demande de licence biologique (BLA) pour le biosimilaire du ranibizumab auprès de la Food and Drug Administration (FDA) américaine.
Varsovie, Pologne–(BUSINESS WIRE)–Le groupe Polpharma Biologics annonce que sa coentreprise créée avec Santo Holding (groupe Strüngmann), Bioeq, a soumis une demande de licence biologique (BLA) auprès de la Food and Drug Administration (FDA) américai…
Riassunto: Il gruppo Polpharma Biologics annuncia la presentazione, da parte della sua joint venture Bioeq, di una domanda di licenza biologica (BLA) per Ranibizumab biosimilare alla Food and Drug Administration (FDA) degli Stati Uniti
VARSAVIA, Polonia–(BUSINESS WIRE)–Il gruppo Polpharma Biologics annuncia che Bioeq, la sua joint venture con Santo Holding (Strüngmann Group), ha presentato una domanda di licenza biologica (BLA) alla Food and Drug Administration (FDA) degli Stati Un…
Die Polpharma Biologics Group meldet, dass ihr Joint-Venture-Unternehmen Bioeq für das Ranibizumab-Biosimilar einen Biologika-Lizenzantrag (BLA) bei der FDA eingereicht hat
WARSCHAU, Polen–(BUSINESS WIRE)–Die Polpharma Biologics Group meldet, dass ihr mit der Santo Holding (Strüngmann Group) gegründetes Joint-Venture-Unternehmen Bioeq für den Biosimilar-Kandidaten des Augenarzneimittels Ranibizumab (Lucentis®) einen Bio…
Resumen: Polpharma Biologics Group anuncia que su empresa en participación Bioeq ha presentado una solicitud de licencia biológica (BLA) para el biosimilar ranibizumab ante la FDA estadounidense
VARSOVIA, Polonia–(BUSINESS WIRE)–Polpharma Biologics Group anuncia que su empresa en participación con Santo Holding (Strüngmann Group), Bioeq, ha presentado una solicitud de licencia biológica (BLA, por sus siglas en inglés) ante la administración …
Samenvatting: Polpharma Biologics Group kondigt aan dat haar joint venture Bioeq een Biologics License Application (BLA) voor Biosimilar Ranibizumab heeft ingediend bij de Amerikaanse Food and Drug Administration (FDA)
WARSCHAU, Polen–(BUSINESS WIRE)–Polpharma Biologics Group kondigt aan dat haar joint venture met Santo Holding (Strüngmann Group), Bioeq, een biologische licentieaanvraag (BLA) heeft ingediend bij de Amerikaanse Food and Drug Administration (FDA) voo…
Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
WARSAW, Poland–(BUSINESS WIRE)– #biologics–Polpharma Biologics Group joint venture Bioeq has submitted a BLA for biosimilar Ranibizumab.
Glaukos Corporation Announces Second Quarter 2021 Financial Results
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced finan…